Macrogenics (Macrogenics) Retained Earnings : $-1,102.75 Mil (As of Dec. 2023)

View and export this data going back to 2013. Start your Free Trial

What is Macrogenics Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Macrogenics's retained earnings for the quarter that ended in Dec. 2023 was $-1,102.75 Mil.

Macrogenics's quarterly retained earnings increased from Jun. 2023 ($-1,074.23 Mil) to Sep. 2023 ($-1,056.68 Mil) but then declined from Sep. 2023 ($-1,056.68 Mil) to Dec. 2023 ($-1,102.75 Mil).

Macrogenics's annual retained earnings declined from Dec. 2021 ($-973.94 Mil) to Dec. 2022 ($-1,093.69 Mil) and declined from Dec. 2022 ($-1,093.69 Mil) to Dec. 2023 ($-1,102.75 Mil).

Macrogenics Retained Earnings Historical Data

The historical data trend for Macrogenics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Macrogenics Retained Earnings Chart

Macrogenics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-642.08

-771.82

-973.94

-1,093.69

-1,102.75

Macrogenics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-1,093.69	-1,131.70	-1,074.23	-1,056.68	-1,102.75

Macrogenics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Macrogenics (NAS:MGNX) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Macrogenics (Macrogenics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Macrogenics Inc (NAS:MGNX) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

M55:Germany

Address

9704 Medical Center Drive, Rockville, MD, USA, 20850

Website

https://www.macrogenics.com

Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. The company's strategy includes leveraging partnerships with a therapeutic focus geared toward developing a broad portfolio of pipeline candidates. The company also targets autoimmune disorders and infectious diseases. The company's intellectual property is characterized by its patent use to protect the composition of its product candidates and the technology used to create them.

Executives

Ezio Bonvini	officer: Sr VP, Research & CSO	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Target N V	10 percent owner	ARA HILL TOP BUILDING, UNIT A-5, PLETTERIJWEG OOST 1, CURACAO, WILLEMSTAD P8 000000
Edward Hurwitz	director
Jeffrey Stuart Peters	officer: Acting General Counsel	9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Margaret Liu	director	C/O SANGAMO, POINT RICHMOND TECH CNTR II, 501 CANAL BLVD, SUITE A-100, RICHMOND CA 94804
Meenu Chhabra	director	C/O VALLON PHARAMCEUTICALS, INC., 100 N 18TH, STREET, SUITE 300, PHILADELPHIA PA 19103
James Karrels	officer: SVP, CFO and Secretary	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
William K Heiden	director	C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Thomas Spitznagel	officer: Sr VP, BPD & Manufacturing	9704 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Biotech Ag Bb	10 percent owner	SCHWERTSTRASSE 6, SCHAFFHAUSEN V8 8200
Federica F. O'brien	director	C/O TELA BIO, INC., 1 GREAT VALLEY PARKWAY, SUITE 24, MALVERN PA 19355
Eric Blasius Risser	officer: Sr VP & Chief Business Officer	9640 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Kenneth Galbraith	director	OCEAN PARK RPO PO BOX 45025, 12851 16TH AVE, SURREY A1 V4A9L1
Stephen L. Eck	officer: Chief Medical Officer	12212 TECHNOLOGY BLVD., AUSTIN TX 78727
Matthew K Fust	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949